Neurobiol Dis 31 (2), 198208
Beyond glucose lowering, GLP-1 RAs have been shown to confer broad cardioprotective benefits including reductions in body weight, blood pressure, postprandial lipids, and inflammation [2]
In a research note published Thursday, JPMorgan analyst Chris Schott estimated it will hit the market in 2028
These changes result from disrupted signaling between dermal papilla cells and matrix keratinocytes, decreased growth factor expression, and reduced proliferation in the follicular bulb [2, 27]
It is instructive that the 2021 EUGOGO guidelines include Se supplementation in the treatment regimen for mild GO, recommending a 6-month treatment with Se preparations for patients with mild GO of short duration to prevent the progression to more severe forms of GO (34)
Resources on maintaining weight loss after tirzepatide , managing semaglutide discontinuation , and the tirzepatide tapering process support the transition from active loss to maintenance effectively